

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Attn: Mr. Shakeel Ahmed
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 9, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Lata Olivier

Lata Olivier



PATENT
Attorney Docket No.: 015280-485100US
Client Ref. No.: E-090-2003/0-US-03
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BERZOFSKY *et al.*

Application No.: 10/582,703

Filed: June 12, 2006

For: IMMUNOGENIC PEPTIDES OF
XAGE-1

Confirmation No. 4573

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Attn: Mr. Shakeel Ahmed
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed February 22, 2007, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification as follows.

Appl. No. 10/582,703

Amdt. dated May 9, 2007

Reply to Notification of Missing Requirements of February 22, 2007

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 6 of this paper.